Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of DURAVYU ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

Biosimilars drove this increase with a 30% CER rise, while generics grew 2% CER. Core EBITDA for the second half was $40 million above consensus, with a full-year margin of 20.1%, exceeding the 19.7% ...

EyePoint Pharmaceuticals also highlights its state-of-the-art cGMP manufacturing facility in Northbridge, MA, which is ready ...